ORPHA:1270
Bowen-Conradi syndrome
Also known as: Bowen syndrome, Hutterite type
Publications
640
Trials
0
Interventional, condition-specific
Researchers
500
Distinct authors in sample
Gene link
EMG1
Strong
Readiness
4/6
Stages with a signal
Clinical definition (Orphanet)
A rare developmental defect during embryogenesis characterized by moderate to severe and postnatal growth retardation, microcephaly, a distinctive facial appearance, profound psychomotor delay, hip and knee contractures and rockerbottom feet.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0008879
- MeSH:C537081
- OMIM:211180
- UMLS:C1859405
Additional Mondo synonyms (5)
BWCNS · Bowen Hutterite Syndrome · Bowen Hutterite syndrome (formerly) · Bowen Hutterite syndrome, formerly · Bowen-Conradi Hutterite syndrome
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
4/6 stages with a signal
No matched interventional trial, but a gene association and an animal model are on record — often described as translation-ready / stalled at the clinical step.
- Gene identifiedPresent
Strong — EMG1
- LiteraturePresent
640 matched papers (464 in last 10 years) Source
- Phenotype characterisedPresent
26 HPO annotations (e.g. Sloping forehead; Joint stiffness; Severe postnatal growth retardation) Source
- Animal modelPresent
1 genotype model (Mus musculus) Source
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (EMG1).
GenCC classification: Strong.
Phenotypes (Monarch / HPO)
26
Associated phenotypes · MONDO:0008879
- Sloping forehead
- Joint stiffness
- Severe postnatal growth retardation
- Severe global developmental delay
- Clinodactyly of the 5th finger
Showing 5 of 26 — open Monarch for the full list.
Animal models (Monarch / Alliance)
1
Model associations linked to this Mondo ID
- Emg1tm1.1Btr/Emg1tm1.1Btr [background:] involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1·MGI:5787933·Mus musculus
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
640
640 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
640 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
464 in the last 10 years · low confidence
Phrase hits: 107 · MeSH hits: 0
Who's working on it?
500
Distinct author names in 107 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Bohnsack MT11 papers · 2019
Centre for Biochemistry and Molecular Cell Biology, Georg-August University, 37073 Göttingen, Germany
Papers in Europe PMC - 02Entian KD7 papers · 2022
c Institute for Molecular Biosciences, Goethe University , Frankfurt am Main , Germany.
Papers in Europe PMC - 03Baserga SJ6 papers · 2021
Departments of Genetics, Molecular Biophysics and Biochemistry, and Therapeutic Radiology, Yale University School of Medicine, New Haven, CT, 06520, USA.
Papers in Europe PMC - 04Lowry RB5 papers · 2005
Department of Medical Genetics, Alberta Children's Hospital and the University of Calgary, Canada. brian.lowry@calgaryhealthregion.ca
Papers in Europe PMC - 05Triggs-Raine B5 papers · 2016
Departments of Biochemistry & Medical GeneticsUniversity of ManitobaWinnipegCanada; Pediatrics & Child HealthUniversity of Manitoba745 Bannatyne Ave.WinnipegMB R3E 0J9Canada; The Manitoba Institute of Child Health513-715 McDermot Ave.WinnipegMB R3E 3P4Canada.
Papers in Europe PMC - 06Greenberg CR4 papers · 2016
Departments of Biochemistry & Medical GeneticsUniversity of ManitobaWinnipegCanada; Pediatrics & Child HealthUniversity of Manitoba745 Bannatyne Ave.WinnipegMB R3E 0J9Canada; The Manitoba Institute of Child Health513-715 McDermot Ave.WinnipegMB R3E 3P4Canada.
Papers in Europe PMC - 07Innes AM4 papers · 2016
Department of Medical Genetics Alberta Children's Hospital and Alberta Children's Hospital Research Institute for Child and Maternal Health Cumming School of Medicine University of Calgary Calgary Alberta Canada.
Papers in Europe PMC - 08Kötter P4 papers · 2012Papers in Europe PMC
- 09Meyer B4 papers · 2011
Cluster of Excellence Frankfurt: Macromolecular Complexes, Max-von-Laue Str. 9, D-60438 Frankfurt/M., Germany.
Papers in Europe PMC - 10Patel N4 papers · 2015
Department of Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, Manitoba, Canada.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
low confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-29
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Bowen-Conradi syndrome — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
("Bowen-Conradi syndrome" OR "Bowen syndrome, Hutterite type" OR "BWCNS" OR "Bowen Hutterite Syndrome" OR "Bowen Hutterite syndrome (formerly)" OR "Bowen Hutterite syndrome, formerly" OR "Bowen-Conradi Hutterite syndrome") OR ("EMG1" OR "EMG1 syndrome" OR "EMG1-related")ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Bowen-Conradi syndrome" OR "Bowen syndrome, Hutterite type" OR "BWCNS" OR "Bowen Hutterite Syndrome" OR "Bowen Hutterite syndrome (formerly)" OR "Bowen Hutterite syndrome, formerly" OR "Bowen-Conradi Hutterite syndrome"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (640) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity
Ingested 2026-07-26T16:53:25.264Z
